Q32 Bio (QTTB) Director Kathleen LaPorte Receives Option Award

What Happened
Kathleen LaPorte, a director of Q32 Bio, received a grant of 10,826 derivative shares (an option award) on June 12, 2026. The reported acquisition amount is $0.00 (typical for option grants as reported on Form 4); the exercise price and total economic value are not disclosed in the provided excerpt. This filing is an amendment to the Form 4 originally filed June 16, 2026 to correct the number of options awarded.

Key Details

• Transaction date: June 12, 2026 (original Form 4 filed June 16, 2026; amended Form 4 filed July 21, 2026). (Footnote F1: amendment solely to correct the number of options.)
• Transaction type: Grant/Award of derivative securities (options) — 10,826 shares @ $0.00 reported.
• Vesting/Exercise terms: The underlying shares shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service (Footnote F2).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: The original Form 4 was filed June 16, 2026 (within the usual two-business-day window); this filing is an amendment to correct the award details.

Context
This was a compensation award (an option grant) to a director and will not result in immediate stock ownership until the options vest and are exercised. Director option awards are common as part of board compensation and do not by themselves indicate the director’s intent to buy or sell stock.